AMGEN INC
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
| Item 2. | PROPERTIES |
|---|
As of December 31, 2024, we owned or leased approximately 160 properties. The locations and primary functions of significant properties are summarized in the following tables:
| U.S. Location: | Manufacturing | Administrative | R&D | Sales & marketing | Warehouse | Distribution center |
|---|---|---|---|---|---|---|
| Thousand Oaks, CA(1) | x | x | x | x | x | x |
| Juncos, Puerto Rico | x | x | x | x | ||
| West Greenwich, RI | x | x | x | |||
| Deerfield, IL | x | x | x | |||
| Cambridge, MA | x | |||||
| New Albany, OH | x | x | x | |||
| San Francisco, CA | x | |||||
| Tampa, FL | x | x | ||||
| Louisville, KY | x | x | ||||
| Other U.S. cities(2) | x | x | x | |||
| ROW Location: | Manufacturing | Administrative | R&D | Sales & marketing | Warehouse | Distribution center |
|---|---|---|---|---|---|---|
| Brazil | x | x | ||||
| Canada | x | x | x | |||
| China | x | x | ||||
| Denmark | x | x | x | |||
| Germany | x | x | x | |||
| Iceland | x | x | ||||
| India | x | |||||
| Ireland | x | x | x | x | x | |
| Netherlands | x | x | x | x | x | |
| Singapore | x | x | x | x | ||
| United Kingdom | x | x | x | |||
| Other countries(2) | x | x | x | x | ||
(1)Corporate headquarters
(2)Includes smaller properties in other U.S. and ROW locations, primarily for administrative and sales & marketing
Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. Additionally, in 2024 we received FDA licensure of our manufacturing facility in New Albany, Ohio; opened a new technology and innovation site in India; and continued to progress on the construction of our first drug substance manufacturing facility in Holly Springs, North Carolina. Furthermore, in January 2025, we broke ground on our second drug substance manufacturing facility in Holly Springs, North Carolina. There are no material encumbrances on our owned properties.
We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item 1A. Risk Factors for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.
See Item 1. Business—Manufacturing, Distribution and Raw Materials.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.